Pharmaceutical Technology

FEBRUARY 29, 2024

LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.

Drugs 264

Drugs Trials 264

pharmaphorum

DECEMBER 23, 2021

The designation – which is awarded to therapies that could represent a significant improvement over standard of care in either efficacy, safety, or both – has been awarded on the strength of phase 1 results in patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC).

Drugs 72

Drugs Antibody Clinical Trials Clinical Trials 72

pharmaphorum

JANUARY 5, 2022

The c-Met protein thought to be both a driver of cancer itself, as well as a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies, including EGFR inhibitors. The post FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag appeared first on.

Antibody 111

Antibody Drugs Protein Gene 111

pharmaphorum

JULY 25, 2022

That alliance also yielded $6 billion blockbuster Darzalex as well as Rybrevant (amivantamab), J&J’s first bispecific antibody which is used to treat EGFR-mutated non-small cell lung cancer (NSCLC). Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.

Antibody 52

Antibody Medicine Drugs Trials 52

Delveinsight

FEBRUARY 23, 2021

The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform. The company develops transformative biologics including vaccines and therapeutics for the world’s most debilitating diseases.

In-Vitro 52

In-Vitro Vaccination Vaccine Licensing 52

XTalks

JANUARY 19, 2024

Since every pharmaceutical is unique, closely monitoring labs such as estimated glomerular filtration rate (eGFR) to detect any changes in renal function with increasing exposures is also critical. As noted earlier, the accumulated dose within the kidneys is also an important consideration during the dose selection process.

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

NOVEMBER 13, 2023

Kathya Rashida de la Luz Hernandez, PhD, Head, Analytical, Center of Molecular Immunology, on: ‘Development of a new high-concentrated formulation of anti-tumour mAbs for subcutaneous administration: Anti-EGFR mAb study case’.

Protein 59

Protein Antibody Engineer Scientist 59